Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation

Next Previous
Trial Profile

A Phase 1/2, Drug-Drug Interaction Study of FDL169 and FDL176 in Healthy Subjects and in Cystic Fibrosis Subjects Homozygous for the F508del-CFTR Mutation

Status: Suspended
Phase of Trial: Phase I/II

Latest Information Update: 04 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FDL 169 (Primary) ; FDL 176 (Primary)
  • Indications Cystic fibrosis
  • Focus Pharmacokinetics
  • Sponsors Flatley Discovery Lab

Most Recent Events

  • 30 Jan 2020 Status changed from recruiting to suspended.
  • 30 Jul 2019 Protocol has been amended due to change in treatment arms from two to four, phase from I to phase I/II and design keywords from open label to double blind.
  • 30 Jul 2019 Planned number of patients changed from 32 to 78.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top